We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
+11.45%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$76M
AUM Growth
-$11.1M
(-13%)
Cap. Flow
+$112M
Cap. Flow
% of AUM
147.28%
Top 10 Holdings %
Top 10 Hldgs %
38.02%
Holding
408
New
159
Increased
53
Reduced
54
Closed
131
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$3.17M |
| 2 |
K
Kellanova
K
|
+$2.19M |
| 3 |
FL
Foot Locker
FL
|
+$2.04M |
| 4 |
General Mills
GIS
|
+$1.95M |
| 5 |
lululemon athletica
LULU
|
+$1.74M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$9.7M |
| 2 |
JPMorgan Chase
JPM
|
+$3.58M |
| 3 |
Gilead Sciences
GILD
|
+$3.38M |
| 4 |
Constellation Brands
STZ
|
+$2.74M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.66% |
| 2 | Consumer Staples | 16.16% |
| 3 | Consumer Discretionary | 9.31% |
| 4 | Communication Services | 3.38% |
| 5 | Materials | 2.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AZPN
176
CALL
DELISTED
ASPEN TECHNOLOGY INC
AZPN
| $31K | 0.04% |
+7,300
| New | +$31K |
|
177
PUT
Hain Celestial
HAIN
$47.8M
| $30K | 0.04% |
+17,000
| New | +$640K |
|
178
CALL
Bank OZK
OZK
$5.61B
| $30K | 0.04% |
+10,000
| New | +$538K |
|
179
CALL
Sarepta Therapeutics
SRPT
$1.78B
| $30K | 0.04% |
16,000
-90,200
| -85% | -$2.79M |
|
180
CALL
Verizon
VZ
$182B
| $30K | 0.04% |
17,500
-32,500
| -65% | -$1.63M |
|
181
CALL
SCYNEXIS
SCYX
$38.7M
| $29K | 0.04% |
+413
| New | +$104K |
|
|
XLNX
182
PUT
DELISTED
Xilinx Inc
XLNX
| $29K | 0.04% |
11,700
-13,900
| -54% | -$817K |
|
183
PUT
Alphabet (Google) Class A
GOOGL
$4.3T
| $28K | 0.04% |
+30,000
| New | +$1.26M |
|
|
K
184
CALL
DELISTED
Kellanova
K
| $28K | 0.04% |
90,525
+79,875
| +750% | +$5.51M |
|
|
185
PUT
Constellation Brands
STZ
$22.9B
| $28K | 0.04% |
19,000
-1,000
| -5% | -$156K |
|
|
OTIC
186
PUT
DELISTED
Otonomy, Inc.
OTIC
| $28K | 0.04% |
+15,000
| New | +$218K |
|
|
DNKN
187
CALL
DELISTED
Dunkin' Brands Group, Inc.
DNKN
| $28K | 0.04% |
27,100
+22,600
| +502% | +$1.21M |
|
188
PUT
Johnson & Johnson
JNJ
$599B
| $27K | 0.04% |
+57,500
| New | +$6.87M |
|
189
CALL
Microsoft
MSFT
$2.99T
| $27K | 0.04% |
7,500
-11,900
| -61% | -$763K |
|
190
PUT
Ligand Pharmaceuticals
LGND
$5.89B
| $26K | 0.03% |
+32,060
| New | +$2.11M |
|
|
BWLD
191
CALL
DELISTED
Buffalo Wild Wings, Inc.
BWLD
| $26K | 0.03% |
+20,000
| New | +$3.05M |
|
192
PUT
Amgen
AMGN
$197B
| $24K | 0.03% |
+12,600
| New | +$2.09M |
|
|
B
193
PUT
Barrick Mining
B
$58.5B
| $24K | 0.03% |
+33,500
| New | +$618K |
|
194
PUT
Karyopharm Therapeutics
KPTI
$169M
| $23K | 0.03% |
+1,333
| New | +$214K |
|
195
Bausch Health
BHC
$1.75B
| $22K | 0.03% |
2,000
-3,182
| -61% | -$43.8K |
|
196
PUT
Newmont
NEM
$95.2B
| $22K | 0.03% |
+19,600
| New | +$685K |
|
197
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
| $22K | 0.03% |
+10,000
| New | +$672K |
|
|
198
PUT
Microsoft
MSFT
$2.99T
| $21K | 0.03% |
44,300
+30,000
| +210% | +$1.92M |
|
199
CALL
Tyson Foods
TSN
$20.4B
| $21K | 0.03% |
+40,600
| New | +$2.56M |
|
200
PUT
Corbus Pharmaceuticals
CRBP
$165M
| $20K | 0.03% |
+887
| New | +$218K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q1 2017 Portfolio in Review
As of Q1 2017, FT Options held 408 positions worth $76M, down 13% from $87.1M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
FT Options deployed $112M of net new capital in Q1 2017, opening 159 new positions and adding to 53 existing holdings. Its largest new stake was GW Pharmaceuticals Plc American Depositary Shares: 25,829 shares worth $3.12M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 45% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $9.7M trimmed.
- FT Options's largest Q1 2017 buy was GW Pharmaceuticals Plc American Depositary Shares: 25,829 shares worth $3.12M.
- FT Options added most to Kellanova in Q1 2017, an estimated $2.19M increase.
- FT Options's biggest Q1 2017 reduction was Regeneron Pharmaceuticals, cutting an estimated $9.7M.
- FT Options fully exited JPMorgan Chase in Q1 2017, selling an estimated $3.58M.
- FT Options's ten largest holdings make up 38% of its $76M portfolio in Q1 2017.
- FT Options opened 159 new positions and closed 131 in Q1 2017.
- FT Options's portfolio value fell 13% quarter-over-quarter to $76M.
Based on FT Options's 13F filing for Q1 2017, filed 12 May 2017.